Neuroblastoma recurrent

1 trials 1 recruiting MedDRA PT
1 Registered trials
1 Recruiting
1 Unique sponsors
2 Unique IMPs
1 Commercial trials
Drug classes (ATC)
ATC code not specified 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody 1 substance
Colony-stimulating factor 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • Y-mAbs Therapeutics A/S Commercial
    NAXITAMAB; SARGRAMOSTIM
    2023-508587-29-00 5 countries 2018 n=81 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Y-mAbs Therapeutics A/S Commercial 1 Phase II 1
← All indication landscapes